C-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential

Research output: Contribution to journalReview article

Abstract

Although the etiology of Parkinson's disease (PD) is poorly understood, oxidative stress has long been implicated in the pathogenesis of the disease. However, multifaceted and divergent signaling cascades downstream of oxidative stress have posed challenges for researchers to identify a central component of the oxidative stress-induced pathways causing neurodegeneration in PD. Since 2010, c-Abl-a non-receptor tyrosine kinase and an indicator of oxidative stress-has shown remarkable potential as a future promising drug target in PD therapeutics. Although, the constitutively active form of c-Abl, Bcr-Abl, has a long history in chronic myeloid leukemia and acute lymphocytic leukemia, the role of c-Abl in PD and relevant neurodegenerative diseases was completely unknown. Recently, others and we have identified and validated c-Abl as an important pathogenic mediator of the disease, where activated c-Abl emerges as a common link to various PD-related inducers of oxidative stress relevant to both sporadic and familial forms of PD and α-synucleinopathies. This review discusses the role of c-Abl in PD and the latest advancement on c-Abl as a drug target and as a prospective biomarker.

Original languageEnglish (US)
Pages (from-to)589-601
Number of pages13
JournalJournal of Parkinson's Disease
Volume7
Issue number4
DOIs
StatePublished - 2017

Fingerprint

Parkinson Disease
Oxidative Stress
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neurodegenerative Diseases
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Biomarkers
History
Research Personnel

Keywords

  • Alpha-synuclein
  • biomarkers
  • c-Abl
  • c-Abl inhibitors
  • oxidative stress
  • parkin
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

@article{28883068506443e19a217b5474e3842f,
title = "C-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential",
abstract = "Although the etiology of Parkinson's disease (PD) is poorly understood, oxidative stress has long been implicated in the pathogenesis of the disease. However, multifaceted and divergent signaling cascades downstream of oxidative stress have posed challenges for researchers to identify a central component of the oxidative stress-induced pathways causing neurodegeneration in PD. Since 2010, c-Abl-a non-receptor tyrosine kinase and an indicator of oxidative stress-has shown remarkable potential as a future promising drug target in PD therapeutics. Although, the constitutively active form of c-Abl, Bcr-Abl, has a long history in chronic myeloid leukemia and acute lymphocytic leukemia, the role of c-Abl in PD and relevant neurodegenerative diseases was completely unknown. Recently, others and we have identified and validated c-Abl as an important pathogenic mediator of the disease, where activated c-Abl emerges as a common link to various PD-related inducers of oxidative stress relevant to both sporadic and familial forms of PD and α-synucleinopathies. This review discusses the role of c-Abl in PD and the latest advancement on c-Abl as a drug target and as a prospective biomarker.",
keywords = "Alpha-synuclein, biomarkers, c-Abl, c-Abl inhibitors, oxidative stress, parkin, Parkinson's disease",
author = "Saurav Brahmachari and Senthilkumar Karuppagounder and Preston Ge and Saebom Lee and Valina Dawson and Dawson, {Ted M} and Ko, {Hanseok Seok}",
year = "2017",
doi = "10.3233/JPD-171191",
language = "English (US)",
volume = "7",
pages = "589--601",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - C-Abl and Parkinson's Disease

T2 - Mechanisms and Therapeutic Potential

AU - Brahmachari, Saurav

AU - Karuppagounder, Senthilkumar

AU - Ge, Preston

AU - Lee, Saebom

AU - Dawson, Valina

AU - Dawson, Ted M

AU - Ko, Hanseok Seok

PY - 2017

Y1 - 2017

N2 - Although the etiology of Parkinson's disease (PD) is poorly understood, oxidative stress has long been implicated in the pathogenesis of the disease. However, multifaceted and divergent signaling cascades downstream of oxidative stress have posed challenges for researchers to identify a central component of the oxidative stress-induced pathways causing neurodegeneration in PD. Since 2010, c-Abl-a non-receptor tyrosine kinase and an indicator of oxidative stress-has shown remarkable potential as a future promising drug target in PD therapeutics. Although, the constitutively active form of c-Abl, Bcr-Abl, has a long history in chronic myeloid leukemia and acute lymphocytic leukemia, the role of c-Abl in PD and relevant neurodegenerative diseases was completely unknown. Recently, others and we have identified and validated c-Abl as an important pathogenic mediator of the disease, where activated c-Abl emerges as a common link to various PD-related inducers of oxidative stress relevant to both sporadic and familial forms of PD and α-synucleinopathies. This review discusses the role of c-Abl in PD and the latest advancement on c-Abl as a drug target and as a prospective biomarker.

AB - Although the etiology of Parkinson's disease (PD) is poorly understood, oxidative stress has long been implicated in the pathogenesis of the disease. However, multifaceted and divergent signaling cascades downstream of oxidative stress have posed challenges for researchers to identify a central component of the oxidative stress-induced pathways causing neurodegeneration in PD. Since 2010, c-Abl-a non-receptor tyrosine kinase and an indicator of oxidative stress-has shown remarkable potential as a future promising drug target in PD therapeutics. Although, the constitutively active form of c-Abl, Bcr-Abl, has a long history in chronic myeloid leukemia and acute lymphocytic leukemia, the role of c-Abl in PD and relevant neurodegenerative diseases was completely unknown. Recently, others and we have identified and validated c-Abl as an important pathogenic mediator of the disease, where activated c-Abl emerges as a common link to various PD-related inducers of oxidative stress relevant to both sporadic and familial forms of PD and α-synucleinopathies. This review discusses the role of c-Abl in PD and the latest advancement on c-Abl as a drug target and as a prospective biomarker.

KW - Alpha-synuclein

KW - biomarkers

KW - c-Abl

KW - c-Abl inhibitors

KW - oxidative stress

KW - parkin

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85032815362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032815362&partnerID=8YFLogxK

U2 - 10.3233/JPD-171191

DO - 10.3233/JPD-171191

M3 - Review article

C2 - 29103051

AN - SCOPUS:85032815362

VL - 7

SP - 589

EP - 601

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 4

ER -